Vinson & Elkins’ Licensing & Technology Transfer lawyers work closely with our clients to align their technology transactions with their business goals. Robust technology agreements offer clients the ability to monetize intellectual property assets, have the freedom to operate, fund R&D, and spark innovation. Our clients continually focus on new technologies—so do we. Whether via strategic external investment, internal development, or multiparty collaborations, we help clients gain access to and make smart investments in the right technology.
Our team works closely with clients to support their commercial objectives. We help plan, manage, negotiate, draft, and close national and international investments, and collaborations involving various products, technology, and intellectual property rights.
Because of our breadth and depth of experience with substantive intellectual property law and our technical acuity, we often conduct the intellectual property due diligence for the transactions we negotiate. This approach creates efficiencies for our clients, and helps ensure that critical intellectual property assets are protected in these transactions.
Developer in drafting and negotiation of license agreements for the intellectual property required to engineer, construct, and operate a multi-billion dollar carbon capture plant in UAE
Duke Energy, as licensee, in counseling regarding effect of licensor’s bankruptcy on licensed intellectual property related to batteries
Represented Velocys in negotiating license and equipment agreements regarding microchannel process technology in the energy and chemical businesses
Represented an e-commerce energy and petrochemical business-to-business exchange owned by major oil companies in drafting and negotiation of software licensing agreements and software development agreements to secure key value-added software products, membership agreements, and privacy issues
Represented a biotechnology company regarding settlement agreement related to dispute involving supply agreement for delivery system for growth hormone technologies
Pharmaceutical company in a world-wide, exclusive license, development and collaboration agreement for the development of an early stage drug product to treat pain for an up-front payment of $41 million, along with additional milestone payments and tiered royalties
Represented international investment management company on a royalty purchase agreement for sales of FDA-approved drug in the U.S., which involved managing the interests of multiple parties, including negotiating and drafting ancillary agreements with interested parties
As outside counsel, handled the IP issues in connection with the acquisition of a North American gas storage and transportation business valued at about $1.5 billion